Receptor Tyrosine Kinases, Volume 147 in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research in the area of Receptor Tyrosine Kinases (RTKs) in the context of major basic science and translational advances, their importance in the development of a large number of anti-cancer drugs over the decades, and a peek into postulated advances in the coming decades for a number of RTK. Chapters in this new release are contributed by a group of International leading scientists who have a rich history in this field.
- Provides the latest information on core advances in receptor tyrosine kinases in cancer research
- Offers outstanding and original reviews on a range of cancer research topics by leading authorities in the field
- Serves as an indispensable reference for faculty, researchers and students alike
About the Author
Table of Contents
Contributions from: Yosef Yarden, Ph.D., Weizmann Institute of Science, ISRAEL Rakesh Kumar, Ph.D., Rajiv Gandhi Center for Biotechnology, INDIA Paul Fisher, M.D., Ph.D., Virginia Commonwealth University, School of Medicine, USA Mark Moasser, M.D., University of California San Francisco, USA William J. Muller, Ph.D., McGill University, CANADA Ravi Salgia, M.D., Ph.D., City of Hope's Comprehensive Cancer Center, USA Renata Pasqualini, Ph.D., Rutgers NJ School of Medicine, USA Fernanda Staquicini, Ph.D., Rutgers NJ School of Medicine, USA M. Radhakrishna Pillai, Ph.D., Rajiv Gandhi Center for Biotechnology, INDIA Mien-Chie Hung, Ph.D., China Medical University, TAIWAN E. Prem Reddy, Ph.D., Mount Sanai School of Medicine, USA Doug Yee, M.D., Masonic Cancer Center University of Minnesota, USA Nandini Verma, Ph.D., Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, INDIA Masakazu Toi, M.D., Ph.D., Kyoto University School of Medicine, JAPAN Louis Chow, M.D., UNIMED Medical Institute, Hong Kong, CHINA Luis Marques da Costa, M.D., Ph.D., University of Lisbon School of Medicine, PORTUGAL